Questions over dual use and whether menthol flavours would attract at-risk groups led the start of the long-awaited Food and Drug Administration (FDA) hearing for Philip Morris International (PMI)’s modified risk claim for its IQOS heated-tobacco product
Restricted content. Do you want to read more?
The data or analysis report you have tried to access is restricted to our subscribers. We invite you to take a free trial below where you will get access to a limited set of our content.
You can find available reports for purchase in our
online store. Reports not listed in the store are available under request. If you are interested in a subscription, get in contact to discuss our subscription plans or to upgrade your current access.
ECigIntelligence is an independent service providing market and regulatory tracking and analysis, for professionals in the e-cigarette and ENDS sectors worldwide.
Our subscribers gain insight and up-to-date intelligence to manage business risk, and the confidence to make informed strategic decisions.